[1]
Deyev, S.M.; Lebedenko, E.N. Modern technologies for creating synthetic antibodies for clinical application. Acta Naturae, 2009, 1(1), 32-50.
[2]
Pluen, A.; Boucher, Y.; Ramanujan, S.; McKee, T.D.; Gohongi, T.; di Tomaso, E.; Brown, E.B.; Izumi, Y.; Campbell, R.B.; Berk, D.A.; Jain, R.K. Role of tumor-host interactions in interstitial diffusion of macromolecules: cranial vs. subcutaneous tumors. Proc. Natl. Acad. Sci. USA, 2001, 98(8), 4628-4633.
[3]
Khawli, L.A.; Biela, B.; Hu, P.; Epstein, A.L. Comparison of recombinant derivatives of chimeric TNT-3 antibody for the radioimaging of solid tumors. Hybrid. Hybridomics, 2003, 22(1), 1-9.
[4]
Tahtis, K.; Lee, F.T.; Smyth, F.E.; Power, B.E.; Renner, C.; Brechbiel, M.W.; Old, L.J.; Hudson, P.J.; Scott, A.M. Biodistribution properties of (111)indium-labeled C-functionalized trans-cyclohexyl diethylenetriaminepentaacetic acid humanized 3S193 diabody and F(ab’)(2) constructs in a breast carcinoma xenograft model. Clin. Cancer Res., 2001, 7(4), 1061-1072.
[5]
Thurber, G.M.; Wittrup, K.D. Quantitative spatiotemporal analysis of antibody fragment diffusion and endocytic consumption in tumor spheroids. Cancer Res., 2008, 68(9), 3334-3341.
[6]
Hudson, P.J. Recombinant antibody fragments. Curr. Opin. Biotechnol., 1998, 9(4), 395-402.
[7]
Fisher, A.C.; Haitjema, C.H.; Guarino, C.; Çelik, E.; Endicott, C.E.; Reading, C.A.; Merritt, J.H.; Ptak, A.C.; Zhang, S.; DeLisa, M.P. Production of secretory and extracellular N-linked glycoproteins in Escherichia coli. Appl. Environ. Microbiol., 2011, 77(3), 871-881.
[8]
Usta, C.; Turgut, N.T.; Bedel, A. How abciximab might be clinically useful. Int. J. Cardiol., 2016, 222, 1074-1078.
[9]
Moja, L.; Lucenteforte, E.; Kwag, K.H.; Bertele, V.; Cam-pomori, A.; Chakravarthy, U.; D’Amico, R.; Dickersin, K.; Kodjikian, L.; Lindsley, K.; Loke, Y. Maguire., M; Martin, D.F.; Mugelli, A.; Mühlbauer, B.; Püntmann, I.; Reeves, B.; Rogers, C.; Schmucker, C.; Subramanian, M.L.; Virgili, G. Systemic safety of bevacizumab versus ranibizumab for neo-vascular age-related macular degeneration. Cochrane Database Syst. Rev., 2014, 9, CD011230.
[10]
Schmucker, C.; Ehlken, C.; Agostini, H.T.; Antes, G.; Ruecker, G.; Lelgemann, M.; Loke, Y.K. A safety review and meta-analyses of bevacizumab and ranibizumab: Off-label versus goldstandard. PLoS One, 2012, 7(8), e42701.
[11]
Goel, N.; Stephens, S. Certolizumab pegol. MAbs, 2010, 2(2), 137-147.
[12]
Ruiz Garcia, V.; Jobanputra, P.; Burls, A.; Cabello, J.B.; Vela Casasempere, P.; Bort-Marti, S.; Kynaston-Pearson, F.J. Certolizumab pegol (CDP870) for rheumatoid arthritis in adults. Cochrane Database Syst. Rev., 2014, 9(9), CD007649.
[13]
Sandborn, W.J.; Feagan, B.G.; Stoinov, S.; Honiball, P.J.; Rutgeerts, P.; Mason, D.; Bloomfield, R.; Schreiber, S. Certolizumab pegol for the treatment of Crohn’s disease. N. Engl. J. Med., 2007, 357(3), 228-238.
[14]
Mease, P.J.; Fleischmann, R.; Deodhar, A.A.; Wollenhaupt, J.; Khraishi, M.; Kielar, D.; Woltering, F.; Stach, C.; Hoep-ken, B.; Arledge, T.; van der Heijde, D. Effect of certoli-zumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind ran-domized placebo-controlled study (RAPID-PsA). Ann. Rheum. Dis., 2013, 1-8.
[15]
Sieper, J.; Tubergen, A.; Coteur, G.; Woltering, F.; Landewe, R. PMS50 – rapid improvements in patient-reported out-comes with certolizumab pegol in patients with axial spondy-loarthritis, including ankylosing spondylitis and non-radiographic axial spondyloarthritis: 24-week results of a Phase 3 double blind randomized placebo-controlled study. Value Health, 2013, 16(3), A227.
[16]
Goswami, S.; Wang, W.; Arakawa, T.; Ohtake, S. Develop-ments and challenges for mAb-based ttherapeutics. Antibodies (Basel), 2013, 2, 452-500.
[17]
Herrington-Symes, A.P.; Farys, M.; Khalili, H.; Brocchini, S. Antibody fragments: prolonging circulation half-life special issue-antibody research. Adv. Biosci. Biotechnol., 2013, 4, 689-698.
[18]
Nelson, A.L. Antibody fragments: Hope and hype. MAbs, 2010, 2(1), 77-83.
[19]
Reichert, J.M. Antibodies to watch in 2017. MAbs, 2016, 14, 1-15.
[20]
Lonberg, N. Human antibodies from transgenic animals. Nat. Biotechnol., 2005, 23(9), 1117-1125.
[21]
Nelson, A.L.; Reichert, J.M. Development trends for therapeutic antibody fragments. Nat. Biotechnol., 2009, 27(4), 331-337.
[22]
Gramlick, G.; Fossati, G.; Nesbitt, A.; Henry, A.J. Neutrali-zation of soluble and membrane tumour necrosis factor α by infliximab, adalimumab or certolizumab pegol using p55 or p75 TNFα receptor bioassay. Gastroenterology, 2006, 130(4), 697.
[23]
Pollack, C.V., Jr; Reilly, P.A.; Eikelboom, J.; Glund, S.; Verhamme, P.; Bernstein, R.A.; Dubiel, R.; Huisman, M.V.; Hylek, E.M.; Kamphuisen, P.W.; Kreuzer, J.; Levy, J.H.; Sellke, F.W.; Stangier, J.; Steiner, T.; Wang, B.; Kam, C-W.; Weitz, J.I. Idarucizumab for dabigatran reversal. N. Engl. J. Med., 2015, 373(6), 511-520.
[24]
Ip, D.; Syed, H.; Cohen, M. Digoxin specific antibody fragments (Digibind) in digoxin toxicity. BMJ, 2009, 339, b2884.
[25]
Chames, P.; Van Regenmortel, M.; Weiss, E.; Baty, D. Therapeutic antibodies: Successes, limitations and hopes for the future. Br. J. Pharmacol., 2009, 157(2), 220-233.
[26]
Gaudreault, J.; Fei, D.; Rusit, J.; Suboc, P.; Shiu, V. Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration. Invest. Ophthalmol. Vis. Sci., 2005, 46(2), 726-733.
[27]
Shock, A.; Burkly, L.; Wakefield, I.; Peters, C.; Garber, E.; Ferrant, J.; Taylor, F.R.; Su, L.; Hsu, Y.M.; Hutto, D.; Amirkhosravi, A.; Meyer, T.; Francis, J.; Malcolm, S.; Robinson, M.; Brown, D.; Shaw, S.; Foulkes, R.; Lawson, A.; Harari, O.; Bourne, T.; Maloney, A.; Weir, N. CDP7657, an anti-CD40L antibody lacking an Fc domain, inhibits CD40L-dependent immune responses without thrombotic complications: an in vivo study. Arthritis Res. Ther., 2015, 17, 234.
[28]
Hawkins, R.E.; Gore, M.; Shparyk, Y.; Bondar, V.; Gladkov, O.; Ganev, T.; Harza, M.; Polenkov, S.; Bondarenko, I.; Karlov, P.; Karyakin, O.; Khasanov, R.; Hedlund, G.; Forsberg, G.; Nordle, Ö.; Eisen, T. A randomized Phase II/III study of naptumomab estafenatox + IFNα versus IFNα in renal cell carcinoma: final analysis with baseline biomarker subgroup and trend analysis. Clin. Cancer Res., 2016, 22(13), 3172-3181.
[29]
Mamot, C.; Drummond, D.C.; Noble, C.O.; Kallab, V.; Guo, Z.; Hong, K.; Kirpotin, D.B.; Park, J.W. Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo. Cancer Res., 2005, 65(24), 11631-11638.
[30]
Mamot, C.; Ritschard, R.; Vogel, B.; Dieterle, T.; Bubendorf, L.; Hilker, C.; Deuster, S.; Herrmann, R.; Rochlitz, C. Targeting radioimmunother-apy of hepatocellular carcinoma with iodine (131I) metuxi-mab injection: Clinical Phase I/II trials. Int. J. Radiat. Oncol. Biol. Phys., 2006, 65(2), 435-444.
[31]
Chen, Z.N.; Mi, L.; Xu, J.; Song, F.; Zhang, Q.; Zhang, Z.; Xing, J.L.; Bian, H.J.; Jiang, J.L.; Wang, X.H.; Shang, P.; Qian, A.R.; Zhang, S.H.; Li, L.; Li, Y.; Feng, Q.; Yu, X.L.; Feng, Y.; Yang, X.M.; Tian, R.; Wu, Z.B.; Leng, N.; Mo, T.S.; Kuang, A.R.; Tan, T.Z.; Li, Y.C.; Liang, D.R.; Lu, W.S.; Miao, J.; Xu, G.H.; Zhang, Z.H.; Nan, K.J.; Han, J.; Liu, Q.G.; Zhang, H.X.; Zhu, P. Targeting radioimmunotherapy of hepatocellular carcinoma with iodine (131I) metuximab injection: Clinical phase I/II trials. Int. J. Radiat. Oncol. Biol. Phys., 2006, 65(2), 435-444.
[32]
Zhang, M-Y.; Lu, J-J.; Wang, L.; Gao, Z-C.; Hu, H.; Lam Ung, C.O.; Wang, Y-T. Development of monoclonal antibodies in China: Overview and prospects , 2015. BioMed Res. Int2015 Article ID 168935, 10 pages
[33]
Boyer, L.V.; Chase, P.B.; Degan, J.A.; Figge, G.; Buelna-Romero, A.; Luchetti, C.; Alagón, A. Subacute coagulopathy in a randomized, comparative trial of Fab and F(ab’)2 antivenoms. Toxicon, 2013, 74, 101-108.
[34]
Bush, S.P.; Ruha, A-M.; Seifert, S.A.; Morgan, D.L.; Lewis, B.J.; Arnold, T.C.; Clark, R.F.; Meggs, W.J.; Toschlog, E.A.; Borron, S.W.; Figge, G.R.; Sollee, D.R.; Shirazi, F.M.; Wolk, R.; de Chazal, I.; Quan, D.; García-Ubbelohde, W.; Alagón, A.; Gerkin, R.D.; Boyer, L.V. Comparison of F(ab’)2 versus Fab antivenom for pit viper envenomation: a prospective, blinded, multicenter, randomized clinical trial. Clin. Toxicol. (Phila.), 2015, 53(1), 37-45.
[36]
Albrecht, H.; Burke, P.A.; Natarajan, A.; Xiong, C-Y.; Kalicinsky, M.; DeNardo, G.L.; DeNardo, S.J. Production of soluble ScFvs with C-terminal-free thiol for site-specific conjugation or stable dimeric ScFvs on demand. Bioconjug. Chem., 2004, 15(1), 16-26.
[37]
Ahmad, Z.A.; Yeap, S.K.; Ali, A.M.; Ho, W.Y.; Alitheen, N.B.; Hamid, M. scFv Antibody: Principles and clinical applicationClin. Develop. Immunol; , 2012. Vol. 2012, Article ID 980250, 15 pages.
[38]
Gupta, S.K.; Shukla, P. Microbial platform technology for recombinant antibody fragment production: A review. Crit. Rev. Microbiol., 2017, 43(1), 31-42.
[39]
Holliger, P.; Prospero, T.; Winter, G. “Diabodies”: Small bivalent and bispecific antibody fragments. Proc. Natl. Acad. Sci. USA, 1993, 90(14), 6444-6448.
[40]
Iliades, P.; Kortt, A.A.; Hudson, P.J. Triabodies: Single chain Fv fragments without a linker form trivalent trimers. FEBS Lett., 1997, 409(3), 437-441.
[41]
Todorovska, A.; Roovers, R.C.; Dolezal, O.; Kortt, A.A.; Hoogenboom, H.R.; Hudson, P.J. Design and application of diabodies, triabodies and tetrabodies for cancer targeting. J. Immunol. Methods, 2001, 248(1-2), 47-66.
[42]
Turner, D.J.; Ritter, M.A.; George, A.J. Importance of the linker in expression of single-chain Fv antibody fragments: optimisation of peptide sequence using phage display technology. J. Immunol. Methods, 1997, 205(1), 43-54.
[43]
Zdanov, A.; Li, Y.; Bundle, D.R.; Deng, S-J.; MacKenzie, C.R.; Narang, S.A.; Young, N.M.; Cygler, M. Structure of a single-chain antibody variable domain (Fv) fragment complexed with a carbohydrate antigen at 1.7-A resolution. Proc. Natl. Acad. Sci. USA, 1994, 91(14), 6423-6427.
[44]
Kortt, A.A.; Lah, M.; Oddie, G.W.; Gruen, C.L.; Burns, J.E.; Pearce, L.A.; Atwell, J.L.; McCoy, A.J.; Howlett, G.J.; Metzger, D.W.; Webster, R.G.; Hudson, P.J. Single-chain Fv fragments of anti-neuraminidase antibody NC10 containing five- and ten-residue linkers form dimers and with zero-residue linker a trimer. Protein Eng., 1997, 10(4), 423-433.
[45]
Atwell, J.; Breheney, K.A.; Lawrence, L.J.; McCoy, A.J.; Kortt, A.A.; Hudson, P.J. scFv Multimers: Length of the linker between V and V domains dictates precisely the transition between diabodies and triabodies. Protein Eng., 1999, 12(7), 597-604.
[46]
Dolezal, O.; Pearce, L.A.; Lawrence, L.J.; McCoy, A.J.; Hudson, P.J.; Kortt, A.A. ScFv multimers of the anti-neuraminidase antibody NC10: shortening of the linker in single-chain Fv fragment assembled in V(L) to V(H) orientation drives the formation of dimers, trimers, tetramers and higher molecular mass multimers. Protein Eng., 2000, 13(8), 565-574.
[47]
Kortt, A.A.; Dolezal, O.; Power, B.E.; Hudson, P.J. Dimeric and trimeric antibodies: High avidity scFvs for cancer targeting. Biomol. Eng., 2001, 18(3), 95-108.
[48]
Le Gall, F.; Kipriyanov, S.M.; Moldenhauer, G.; Little, M. Di-, tri- and tetrameric single chain Fv antibody fragments against human CD19: effect of valency on cell binding. FEBS Lett., 1999, 453(1-2), 164-168.
[49]
Power, B.E.; Doughty, L.; Shapira, D.R.; Burns, J.E.; Bayly, A.M.; Caine, J.M.; Liu, Z.; Scott, A.M.; Hudson, P.J.; Kortt, A.A. Noncovalent scFv multimers of tumor-targeting anti-Lewis(y) hu3S193 humanized antibody. Protein Sci., 2003, 12(4), 734-747.
[50]
Willuda, J.; Kubetzko, S.; Waibel, R.; Schubiger, P.A.; Zangemeister-Wittke, U.; Plückthun, A. Tumor targeting of mono-, di-, and tetravalent anti-p185(HER-2) miniantibodies multimerized by self-associating peptides. J. Biol. Chem., 2001, 276(17), 14385-14392.
[51]
Asano, R.; Hagiwara, Y.; Koyama, N.; Masakari, Y.; Orimo, R.; Arai, K.; Ogata, H.; Furumoto, S.; Umetsu, M.; Kumagai, I. Multimerization of anti-(epidermal growth factor receptor) IgG fragments induces an antitumor effect: the case for humanized 528 scFv multimers. FEBS J., 2013, 280(19), 4816-4826.
[52]
Asano, R.; Koyama, N.; Hagiwara, Y.; Masakari, Y.; Orimo, R.; Arai, K.; Ogata, H.; Furumoto, S.; Umetsu, M.; Kumagai, I. Anti-EGFR scFv tetramer (tetrabody) with a stable monodisperse structure, strong anticancer effect, and a long in vivo half-life. FEBS Open Bio, 2016, 6(6), 594-602.
[53]
Holliger, P.; Hudson, P.J. Engineered antibody fragments and the rise of single domains. Nat. Biotechnol., 2005, 23(9), 1126-1136.
[54]
Hu, S.; Shively, L.; Raubitschek, A.; Sherman, M.; Williams, L.E.; Wong, J.Y.C.; Shively, J.E.; Wu, A.M. Minibody: A novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid, high-level targeting of xenografts. Cancer Res., 1996, 56(13), 3055-3061.
[55]
Shahied, L.S.; Tang, Y.; Alpaugh, R.K.; Somer, R.; Greenspon, D.; Weiner, L.M. Bispecific minibodies targeting HER2/neu and CD16 exhibit improved tumor lysis when placed in a divalent tumor antigen binding format. J. Biol. Chem., 2004, 279(52), 53907-53914.
[56]
Wörn, A.; Plückthun, A. Stability engineering of antibody single-chain Fv fragments. J. Mol. Biol., 2001, 305(5), 989-1010.
[57]
Tang, Y.; Jiang, N.; Parakh, C.; Hilvert, D. Selection of linkers for a catalytic single-chain antibody using phage display technology. J. Biol. Chem., 1996, 271(26), 15682-15686.
[58]
Kim, Y.P.; Park, D.; Kim, J.J.; Chi, W.J.; Lee, S.H.; Lee, S.Y.; Kim, S.; Chung, J.M.; Jeon, J.; Lee, B.D.; Shin, J.H.; Lee, Y.I.; Cho, H.; Lee, J.M.; Kang, H.C. Effective therapeutic approach for head and neck cancer by an engineered minibody targeting the EGFR receptor. PLoS One, 2014, 9(12), e113442.
[59]
Ayala, M.; Balint, R.F.; Fernández-de-Cossío, L.; Canaán-Haden, J.W.; Larrick, J.W.; Gavilondo, J.V. Variable region sequence modulates periplasmic export of a single-chain Fv antibody fragment in Escherichia coli. Biotechniques, 1995, 18 (5), 832-, 835-838, 840-842
[60]
Watanabe, R.; Hanaoka, H.; Sato, K.; Nagaya, T.; Harada, T.; Mitsunaga, M.; Kim, I.; Paik, C.H.; Wu, A.M.; Choyke, P.L.; Kobayashi, H. Photoimmunotherapy targeting prostate-specific membrane antigen: are antibody fragments as effective as antibodies? J. Nucl. Med., 2015, 56(1), 140-144.
[61]
Chiu, G.N.; Edwards, L.A.; Kapanen, A.I.; Malinen, M.M.; Dragowska, W.H.; Warburton, C.; Chikh, G.G.; Fang, K.Y.; Tan, S.; Sy, J.; Tucker, C.; Waterhouse, D.N.; Klasa, R.; Bally, M.B. Modulation of cancer cell survival pathways using multivalent liposomal therapeutic antibody constructs. Mol. Cancer Ther., 2007, 6(3), 844-855.
[62]
Park, J.W.; Hong, K.; Carter, P.; Asgari, H.; Guo, L.Y.; Keller, G.A.; Wirth, C.; Shalaby, R.; Kotts, C.; Wood, W.I. Development of anti-p185HER2 immunoliposomes for cancer therapy. Proc. Natl. Acad. Sci. USA, 1995, 92(5), 1327-1331.
[63]
Jølck, R.I.; Feldborg, L.N.; Andersen, S.; Moghimi, S.M.; Andresen, T.L. Engineering liposomes and nanoparticles for biological targeting. Adv. Biochem. Eng. Biotechnol., 2011, 125, 251-280.
[64]
Hamers-Casterman, C.; Atarhouch, T.; Muyldermans, S.; Robinson, G.; Hamers, C.; Songa, E.B.; Bendahman, N.; Hamers, R. Naturally occurring antibodies devoid of light chains. Nature, 1993, 363(6428), 446-448.
[65]
Ungar-Waron, H.; Elias, E.; Gluckman, A.; Trainin, Z. Dromedary IgG, purification, characterization and quantita-tion in sera of dams and newborn. Isr. J. Vet. Med., 1987, 43, 198-203.
[66]
De Vos, J.; Devoogdt, N.; Lahoutte, T.; Muyldermans, S. Camelid single-domain antibody-fragment engineering for (pre)clinical in vivo molecular imaging applications: adjusting the bullet to its target. Expert Opin. Biol. Ther., 2013, 13(8), 1149-1160.
[67]
Hassanzadeh-Ghassabeh, G.; Devoogdt, N.; De Pauw, P.; Vincke, C.; Muyldermans, S. Nanobodies and their potential applications. Nanomedicine (Lond.), 2013, 8(6), 1013-1026.
[68]
Flajnik, M.F.; Deschacht, N.; Muyldermans, S. A case of convergence: Why did a simple alternative to canonical antibodies arise in sharks and camels? PLoS Biol., 2011, 9(8), e1001120.
[69]
De Genst, E.; Saerens, D.; Muyldermans, S.; Conrath, K. Antibody repertoire development in camelids. Dev. Comp. Immunol., 2006, 30(1-2), 187-198.
[70]
Roovers, R.C.; van Dongen, G.A. van Bergen en Henegouwen, P.M. Nanobodies in therapeutic applications. Curr. Opin. Mol. Ther., 2007, 9(4), 327-335.
[71]
De Meyer, T.; Muyldermans, S.; Depicker, A. Nanobody-based products as research and diagnostic tools. Trends Biotechnol., 2014, 32(5), 263-270.
[72]
van den Berg, A.; Dowdy, S.F. Protein transduction domain delivery of therapeutic macromolecules. Curr. Opin. Biotechnol., 2011, 22(6), 888-893.
[73]
Abulrob, A.; Sprong, H. Van Bergen en Henegouwen, P.; Stanimirovic, D. The blood-brain barrier transmigrating sin-gle domain antibody: Mechanisms of transport and antigenic epitopes in human brain endothelial cells. J. Neurochem., 2005, 95(4), 1201-1214.
[74]
Lafaye, P.; Achour, I.; England, P.; Duyckaerts, C.; Rougeon, F. Single-domain antibodies recognize selectively small oligomeric forms of amyloid beta, prevent Abeta-induced neurotoxicity and inhibit fibril formation. Mol. Immunol., 2009, 46(4), 695-704.
[75]
Revets, H.; De Baetselier, P.; Muyldermans, S. Nanobodies as novel agents for cancer therapy. Expert Opin. Biol. Ther., 2005, 5(1), 111-124.
[76]
Mujić-Delić, A.; de Wit, R.H.; Verkaar, F.; Smit, M.J. GPCR-targeting nanobodies: Attractive research tools, diagnostics, and therapeutics. Trends Pharmacol. Sci., 2014, 35(5), 247-255.
[77]
Vincke, C.; Muyldermans, S. Introduction to heavy chain antibodies and derived nanobodies. Methods Mol. Biol., 2012, 911, 15-26.
[78]
Cortez-Retamozo, V.; Backmann, N.; Senter, P.D.; Wernery, U.; De Baetselier, P.; Muyldermans, S.; Revets, H. Efficient cancer therapy with a nanobody-based conjugate. Cancer Res., 2004, 64(8), 2853-2857.
[79]
Rahbarizadeh, F.; Ahmadvand, D.; Sharifzadeh, Z. Nanobody; an old concept and new vehicle for immunotargeting. Immunol. Invest., 2011, 40(3), 299-338.
[80]
Sadeqzadeh, E.; Rahbarizadeh, F.; Ahmadvand, D.; Rasaee, M.J.; Parhamifar, L.; Moghimi, S.M. Combined MUC1-specific nanobody-tagged PEG-polyethylenimine polyplex targeting and transcriptional targeting of tBid transgene for directed killing of MUC1 over-expressing tumour cells. J. Control. Release, 2011, 156(1), 85-91.
[81]
Vaneycken, I.; Devoogdt, N.; Van Gassen, N.; Vincke, C.; Xavier, C.; Wernery, U.; Muyldermans, S.; Lahoutte, T.; Caveliers, V. Preclinical screening of anti-HER2 nanobodies for molecular imaging of breast cancer. FASEB J., 2011, 25(7), 2433-2446.
[82]
Sharifzadeh, Z.; Rahbarizadeh, F.; Shokrgozar, M.A.; Ahmadvand, D.; Mahboudi, F.; Jamnani, F.R.; Moghimi, S.M. Genetically engineered T cells bearing chimeric nanoconstructed receptors harboring TAG-72-specific camelid single domain antibodies as targeting agents. Cancer Lett., 2013, 334(2), 237-244.
[83]
Roovers, R.C.; Laeremans, T.; Huang, L.; De Taeye, S.; Verkleij, A.J.; Revets, H.; de Haard, H.J. van Bergen en Henegouwen, P.M. Efficient inhibition of EGFR signalling and of tumour growth by antagonistic anti-EGFR nanobod-ies. Cancer Immunol. Immunother., 2007, 56(3), 303-317.
[84]
Roovers, R.C.; Vosjan, M.J.; Laeremans, T.; el Khoulati, R.; de Bruin, R.C.; Ferguson, K.M.; Verkleij, A.J.; van Dongen, G.A. van Bergen en Henegouwen, P.M. A biparatopic anti-EGFR nanobody efficiently inhibits solid tumour growth. Int. J. Cancer, 2011, 129(8), 2013-2024.
[85]
Slørdahl, T.S.; Denayer, T.; Moen, S.H.; Standal, T.; Børset, M.; Ververken, C.; Rø, T.B. Anti-c-MET Nanobody - a new potential drug in multiple myeloma treatment. Eur. J. Haematol., 2013, 91(5), 399-410.
[86]
Vosjan, M.J.; Vercammen, J.; Kolkman, J.A.; Stigter-van Walsum, M.; Revets, H.; van Dongen, G.A. Nanobodies targeting the hepatocyte growth factor: potential new drugs for molecular cancer therapy. Mol. Cancer Ther., 2012, 11(4), 1017-1025.
[87]
Behdani, M.; Zeinali, S.; Khanahmad, H.; Karimipour, M.; Asadzadeh, N.; Azadmanesh, K.; Khabiri, A.; Schoonooghe, S.; Habibi Anbouhi, M.; Hassanzadeh-Ghassabeh, G.; Muyldermans, S. Generation and characterization of a functional Nanobody against the vascular endothelial growth factor receptor-2; angiogenesis cell receptor. Mol. Immunol., 2012, 50(1-2), 35-41.
[88]
Kijanka, M.; Dorresteijn, B.; Oliveira, S. van Bergen en Henegouwen, P.M. Nanobody-based cancer therapy of solid tumors. Nanomedicine (Lond.), 2015, 10(1), 161-174.
[89]
Stuckey, D.W.; Hingtgen, S.D.; Karakas, N.; Rich, B.E.; Shah, K. Engineering toxin-resistant therapeutic stem cells to treat brain tumors. Stem Cells, 2015, 33(2), 589-600.
[90]
Goyvaerts, C.; De Groeve, K.; Dingemans, J.; Van Lint, S.; Robays, L.; Heirman, C.; Reiser, J.; Zhang, X.Y.; Thielemans, K.; De Baetselier, P.; Raes, G.; Breckpot, K. Development of the Nanobody display technology to target lentiviral vectors to antigen-presenting cells. Gene Ther., 2012, 19(12), 1133-1140.
[91]
Hernot, S.; Unnikrishnan, S.; Du, Z.; Shevchenko, T.; Cosyns, B.; Broisat, A.; Toczek, J.; Caveliers, V.; Muyldermans, S.; Lahoutte, T.; Klibanov, A.L.; Devoogdt, N. Nanobody-coupled microbubbles as novel molecular tracer. J. Control. Release, 2012, 158(2), 346-353.
[92]
Van de Broek, B.; Devoogdt, N.; D’Hollander, A.; Gijs, H-L.; Jans, K.; Lagae, L.; Muyldermans, S.; Maes, G.; Borghs, G. Specific cell targeting with nanobody conjugated branched gold nanoparticles for photothermal therapy. ACS Nano, 2011, 5(6), 4319-4328.
[93]
Altintas, I.; Kok, R.J.; Schiffelers, R.M. Targeting epidermal growth factor receptor in tumors: from conventional monoclonal antibodies via heavy chain-only antibodies to nanobodies. Eur. J. Pharm. Sci., 2012, 45(4), 399-407.
[94]
Shishido, T.; Azumi, Y.; Nakanishi, T.; Umetsu, M.; Tanaka, T.; Ogino, C.; Fukuda, H.; Kondo, A. Biotinylated bionanocapsules for displaying diverse ligands toward cell-specific delivery. J. Biochem., 2009, 146(6), 867-874.
[95]
Talelli, M.; Rijcken, C.J.; Oliveira, S.; van der Meel, R.; van Bergen En Henegouwen, P.M.; Lammers, T.; van Nostrum, C.F.; Storm, G.; Hennink, W.E. Nanobody-shell functionalized thermosensitive core-crosslinked polymeric micelles for active drug targeting. J. Control. Release, 2011, 151(2), 183-192.
[96]
Moores, S.L.; Chiu, M.L.; Bushey, B.S.; Chevalier, K.; Luistro, L.; Dorn, K.; Brezski, R.J.; Haytko, P.; Kelly, T.; Wu, S.J.; Martin, P.L.; Neijssen, J.; Parren, P.W.; Schuurman, J.; Attar, R.M.; Laquerre, S.; Lorenzi, M.V.; Anderson, G.M. A novel bispecific antibody targeting EGFR and cMet is effective against EGFR inhibitor-resistant lung tumors. Cancer Res., 2016, 76(13), 3942-3953.
[97]
Nisonoff, A.; Mandy, W.J. Quantitative estimation of the hybridization of rabbit antibodies. Nature, 1962, 194, 355-359.
[98]
James, N.D.; Atherton, P.J.; Jones, J.; Howie, A.J.; Tchekmedyian, S.; Curnow, R.T. A phase II study of the bispecific antibody MDX-H210 (anti-HER2 x CD64) with GM-CSF in HER2+ advanced prostate cancer. Br. J. Cancer, 2001, 85(2), 152-156.
[99]
Lindhofer, H.; Mocikat, R.; Steipe, B.; Thierfelder, S. Preferential species-restricted heavy/light chain pairing in rat/mouse quadromas. Implications for a single-step purification of bispecific antibodies. J. Immunol., 1995, 155(1), 219-225.
[100]
Byrne, H.; Conroy, P.J.; Whisstock, J.C.; O’Kennedy, R.J. A tale of two specificities: bispecific antibodies for therapeutic and diagnostic applications. Trends Biotechnol., 2013, 31(11), 621-632.
[101]
Linke, R.; Klein, A.; Seimetz, D. Catumaxomab: clinical development and future directions. MAbs, 2010, 2(2), 129-136.
[102]
Heiss, M.M.; Murawa, P.; Koralewski, P.; Kutarska, E.; Kolesnik, O.O.; Ivanchenko, V.V.; Dudnichenko, A.S.; Aleknaviciene, B.; Razbadauskas, A.; Gore, M.; Ganea-Motan, E.; Ciuleanu, T.; Wimberger, P.; Schmittel, A.; Schmalfeldt, B.; Burges, A.; Bokemeyer, C.; Lindhofer, H.; Lahr, A.; Parsons, S.L. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial. Int. J. Cancer, 2010, 127(9), 2209-2221.
[103]
Spiess, C.; Merchant, M.; Huang, A.; Zheng, Z.; Yang, N.Y.; Peng, J.; Ellerman, D.; Shatz, W.; Reilly, D.; Yansura, D.G.; Scheer, J.M. Bispecific antibodies with natural architecture produced by co-culture of bacteria expressing two distinct half-antibodies. Nat. Biotechnol., 2013, 31(8), 753-758.
[104]
Schaefer, W.; Regula, J.T.; Bähner, M.; Schanzer, J.; Croas-dale, R.; Dürr, H.; Gassner, C.; Georges, G.; Kettenberger, H. Imhof-Jung, S.; Schwaiger, M.; Stubenrauch, K.G.; Sustmann, C.; Thomas, M.; Scheuer, W.; Klein, C. Immuno-globulin domain crossover as a generic approach for the pro-duction of bispecific IgG antibodies. Proc. Natl. Acad. Sci. USA, 2011, 108(27), 11187-11192.
[105]
Rossi, E.A.; Goldenberg, D.M.; Cardillo, T.M.; McBride, W.J.; Sharkey, R.M.; Chang, C.H. Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting. Proc. Natl. Acad. Sci. USA, 2006, 103(18), 6841-6846.
[106]
Schuurman, J.; Graus, Y.F.; Labrijn, A.F.; Ruuls, S.; Parren, P.W. Opening the door to innovation. MAbs, 2014, 6(4), 812-819.
[107]
Wu, C.; Ying, H.; Grinnell, C.; Bryant, S.; Miller, R.; Clabbers, A.; Bose, S.; McCarthy, D.; Zhu, R.R.; Santora, L.; Davis-Taber, R.; Kunes, Y.; Fung, E.; Schwartz, A.; Sakorafas, P.; Gu, J.; Tarcsa, E.; Murtaza, A.; Ghayur, T. Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin. Nat. Biotechnol., 2007, 25(11), 1290-1297.
[108]
Spiess, C.; Zhai, Q.; Carter, P.J. Alternative molecular formats and therapeutic applications for bispecific antibodies. Mol. Immunol., 2015, 67(2 Pt A), 95-106.
[109]
Albrecht, H.; Denardo, G.L.; Denardo, S.J. Monospecific bivalent scFv-SH: effects of linker length and location of an engineered cysteine on production, antigen binding activity and free SH accessibility. J. Immunol. Methods, 2006, 310(1-2), 100-116.
[110]
Baeuerle, P.A.; Reinhardt, C. Bispecific T-cell engaging antibodies for cancer therapy. Cancer Res., 2009, 69(12), 4941-4944.
[111]
Müller, D.; Kontermann, R.E. Bispecific antibodies for cancer immunotherapy: Current perspectives. BioDrugs, 2010, 24(2), 89-98.
[112]
Baeuerle, P.A.; Kufer, P.; Bargou, R. BiTE: Teaching antibodies to engage T-cells for cancer therapy. Curr. Opin. Mol. Ther., 2009, 11(1), 22-30.
[113]
Dreier, T.; Lorenczewski, G.; Brandl, C.; Hoffmann, P.; Syring, U.; Hanakam, F.; Kufer, P.; Riethmuller, G.; Bargou, R.; Baeuerle, P.A. Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody. Int. J. Cancer, 2002, 100(6), 690-697.
[114]
Kontermann, R.E.; Brinkmann, U. Bispecific antibodies. Drug Discov. Today, 2015, 20(7), 838-847.
[115]
Moore, P.A.; Zhang, W.; Rainey, G.J.; Burke, S.; Li, H.; Huang, L.; Gorlatov, S.; Veri, M.C.; Aggarwal, S.; Yang, Y.; Shah, K.; Jin, L.; Zhang, S.; He, L.; Zhang, T.; Ciccarone, V.; Koenig, S.; Bonvini, E.; Johnson, S. Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma. Blood, 2011, 117(17), 4542-4551.
[116]
Chen, S.; Li, J.; Li, Q.; Wang, Z. Bispecific antibodies in cancer immunotherapy. Hum. Vaccin. Immunother., 2016, 12(10), 2491-2500.
[117]
Fan, D.; Li, Z.; Zhang, X.; Yang, Y.; Yuan, X.; Zhang, X.; Yang, M.; Zhang, Y.; Xiong, D. AntiCD3Fv fused to human interleukin-3 deletion variant redirected T cells against human acute myeloid leukemic stem cells. J. Hematol. Oncol., 2015, 8(18), 18.
[118]
Fan, G.; Wang, Z.; Hao, M.; Li, J. Bispecific antibodies and their applications. J. Hematol. Oncol., 2015, 8, 130.
[119]
Weiner, G.J. Building better monoclonal antibody-based therapeutics. Nat. Rev. Cancer, 2015, 15(6), 361-370.
[120]
Neri, D.; Sondel, P.M. Immunocytokines for cancer treatment: past, present and future. Curr. Opin. Immunol., 2016, 40, 96-102.
[121]
Chelius, D.; Ruf, P.; Gruber, P.; Plöscher, M.; Liedtke, R.; Gansberger, E.; Hess, J.; Wasiliu, M.; Lindhofer, H. Structural and functional characterization of the trifunctional antibody catumaxomab. MAbs, 2010, 2(3), 309-319.
[122]
Zeidler, R.; Mysliwietz, J.; Csánady, M.; Walz, A.; Ziegler, I.; Schmitt, B.; Wollenberg, B.; Lindhofer, H. The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells. Br. J. Cancer, 2000, 83(2), 261-266.
[123]
Berek, J.S.; Edwards, R.P.; Parker, L.P.; DeMars, L.R.; Herzog, T.J.; Lentz, S.S.; Morris, R.T.; Akerley, W.L.; Holloway, R.W.; Method, M.W.; Plaxe, S.C.; Walker, J.L.; Friccius-Quecke, H.; Krasner, C.N. Catumaxomab for the treatment of malignant ascites in patients with chemotherapy-refractory ovarian cancer: a phase II study. Int. J. Gynecol. Cancer, 2014, 24(9), 1583-1589.
[124]
Seimetz, D.; Lindhofer, H.; Bokemeyer, C. Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy. Cancer Treat. Rev., 2010, 36(6), 458-467.
[125]
Jäger, M.; Schoberth, A.; Ruf, P.; Hess, J.; Lindhofer, H. The trifunctional antibody ertumaxomab destroys tumor cells that express low levels of human epidermal growth factor receptor 2. Cancer Res., 2009, 69(10), 4270-4276.
[126]
Portell, C.A.; Wenzell, C.M.; Advani, A.S. Clinical and pharmacologic aspects of blinatumomab in the treatment of B-cell acute lymphoblastic leukemia. Clin. Pharmacol., 2013, 5(Suppl. 1), 5-11.
[127]
Wolf, E.; Hofmeister, R.; Kufer, P.; Schlereth, B.; Baeuerle, P.A. BiTEs: Bispecific antibody constructs with unique anti-tumor activity. Drug Discov. Today, 2005, 10(18), 1237-1244.
[128]
Bargou, R.; Leo, E.; Zugmaier, G.; Klinger, M.; Goebeler, M.; Knop, S.; Noppeney, R.; Viardot, A.; Hess, G.; Schuler, M.; Einsele, H.; Brandl, C.; Wolf, A.; Kirchinger, P.; Klappers, P.; Schmidt, M.; Riethmüller, G.; Reinhardt, C.; Baeuerle, P.A.; Kufer, P. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science, 2008, 321(5891), 974-977.
[129]
Ribera, J.M.; Ferrer, A.; Ribera, J.; Genescà, E. Profile of blinatumomab and its potential in the treatment of relapsed/refractory acute lymphoblastic leukemia. OncoTargets Ther., 2015, 8, 1567-1574.
[130]
Stieglmaier, J.; Benjamin, J.; Nagorsen, D. Utilizing the BiTE (bispecific T-cell engager) platform for immunotherapy of cancer. Expert Opin. Biol. Ther., 2015, 15(8), 1093-1099.
[131]
Thakur, A.; Lum, L.G. ‘NextGen’ biologics: Bispecific antibodies and emerging clinical results. Expert Opin. Biol. Ther., 2016, 16(5), 675-688.
[132]
Ayyar, B.V.; Arora, S.; O’Kennedy, R. Coming-of-Age of Antibodies in Cancer Therapeutics. Trends Pharmacol. Sci., 2016, 37(12), 1009-1028.
[133]
Liu, L.; Lam, A.; Alderson, R.; Yang, Y.; Li, H.; Long, V.; Gorlatov, S.; Burke, S.; Ciccarone, V.; Nordstrom, J.; John-son, S.; Moore, P.; Bonvini, E. MGD011, humanized CD19 x CD3 DART® protein with enhanced pharmacokinetic properties, demonstrates potent T-cell mediated anti-tumor activity in preclinical models and durable B-cell depletion in cynomolgus monkeys following once-a-week dosing. Blood, 2014, 124, 1775.
[134]
Al-Hussaini, M.; Rettig, M.P.; Ritchey, J.K.; Karpova, D.; Uy, G.L.; Eissenberg, L.G.; Gao, F.; Eades, W.C.; Bonvini, E.; Chichili, G.R.; Moore, P.A.; Johnson, S.; Collins, L.; DiPersio, J.F. Targeting CD123 in acute myeloid leukemia using a T-cell-directed dual-affinity retargeting platform. Blood, 2016, 127(1), 122-131.
[135]
Hurwitz, H.; Crocenzi, T.; Lohr, J.; Bonvini, E.; Johnson, S.; Moore, P.; Wigginton, J. A Phase I, first-in-human, open la-bel, dose escalation study of MGD007, a humanized gpA33 × CD3 dualaffinity retargeting (DART®) protein in patients with relapsed/refractory metastatic colorectal carcinoma. J. Immunother. Cancer, 2014, 2(Suppl. 3), 86.
[136]
Reusch, U.; Burkhardt, C.; Fucek, I.; Le Gall, F.; Le Gall, M.; Hoffmann, K.; Knackmuss, S.H.; Kiprijanov, S.; Little, M.; Zhukovsky, E.A. A novel tetravalent bispecific TandAb (CD30/CD16A) efficiently recruits NK cells for the lysis of CD30+ tumor cells. MAbs, 2014, 6(3), 728-739.
[137]
Rothe, A.; Sasse, S.; Topp, M.S.; Eichenauer, D.A.; Hummel, H.; Reiners, K.S.; Dietlein, M.; Kuhnert, G.; Kessler, J.; Buerkle, C.; Ravic, M.; Knackmuss, S.; Marschner, J.P.; Pogge von Strandmann, E.; Borchmann, P.; Engert, A. A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma. Blood, 2015, 125(26), 4024-4031.
[138]
Reusch, U.; Duell, J.; Ellwanger, K.; Herbrecht, C.; Knackmuss, S.H.; Fucek, I.; Eser, M.; McAleese, F.; Molkenthin, V.; Gall, F.L.; Topp, M.; Little, M.; Zhukovsky, E.A. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells. MAbs, 2015, 7(3), 584-604.
[139]
Hemmerle, T.; Wulhfard, S.; Neri, D. A critical evaluation of the tumor-targeting properties of bispecific antibodies based on quantitative biodistribution data. Protein Eng. Des. Sel., 2012, 25(12), 851-854.
[140]
Pasche, N.; Neri, D. Immunocytokines: A novel class of potent armed antibodies. Drug Discov. Today, 2012, 17(11-12), 583-590.
[141]
Gubbels, J.A.; Gadbaw, B.; Buhtoiarov, I.N.; Horibata, S.; Kapur, A.K.; Patel, D.; Hank, J.A.; Gillies, S.D.; Sondel, P.M.; Patankar, M.S.; Connor, J. Ab-IL2 fusion proteins mediate NK cell immune synapse formation by polarizing CD25 to the target cell-effector cell interface. Cancer Immunol. Immunother., 2011, 60(12), 1789-1800.
[142]
Catania, C.; Maur, M.; Berardi, R.; Rocca, A.; Giacomo, A.M.; Spitaleri, G.; Masini, C.; Pierantoni, C.; González-Iglesias, R.; Zigon, G.; Tasciotti, A.; Giovannoni, L.; Lovato, V.; Elia, G.; Menssen, H.D.; Neri, D.; Cascinu, S.; Conte, P.F.; Braud, Fd. The tumor-targeting immunocytokine F16-IL2 in combination with doxorubicin: dose escalation in patients with advanced solid tumors and expansion into patients with metastatic breast cancer. Cell Adhes. Migr., 2015, 9(1-2), 14-21.
[143]
Gutbrodt, K.L.; Schliemann, C.; Giovannoni, L.; Frey, K.; Pabst, T.; Klapper, W.; Berdel, W.E.; Neri, D. Antibody-based delivery of interleukin-2 to neovasculature has potent activity against acute myeloid leukemia. Sci. Transl. Med., 2013, 5(201), 201ra118.
[144]
Schliemann, C.; Gutbrodt, K.L.; Kerkhoff, A.; Pohlen, M.; Wiebe, S.; Silling, G.; Angenendt, L.; Kessler, T.; Mesters, R.M.; Giovannoni, L.; Schäfers, M.; Altvater, B.; Rossig, C.; Grünewald, I.; Wardelmann, E.; Köhler, G.; Neri, D.; Stelljes, M.; Berdel, W.E. Targeting interleukin-2 to the bone marrow stroma for therapy of acute myeloid leukemia relapsing after allogeneic hematopoietic stem cell transplantation. Cancer Immunol. Res., 2015, 3(5), 547-556.
[145]
Johannsen, M.; Spitaleri, G.; Curigliano, G.; Roigas, J.; Weikert, S.; Kempkensteffen, C.; Roemer, A.; Kloeters, C.; Rogalla, P.; Pecher, G.; Miller, K.; Berndt, A.; Kosmehl, H.; Trachsel, E.; Kaspar, M.; Lovato, V.; González-Iglesias, R.; Giovannoni, L.; Menssen, H.D.; Neri, D.; de Braud, F. The tumour-targeting human L19-IL2 immunocytokine: preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma. Eur. J. Cancer, 2010, 46(16), 2926-2935.
[146]
Eigentler, T.K.; Weide, B.; de Braud, F.; Spitaleri, G.; Romanini, A.; Pflugfelder, A.; González-Iglesias, R.; Tasciotti, A.; Giovannoni, L.; Schwager, K.; Lovato, V.; Kaspar, M.; Trachsel, E.; Menssen, H.D.; Neri, D.; Garbe, C. A dose-escalation and signal-generating study of the immunocytokine L19-IL2 in combination with dacarbazine for the therapy of patients with metastatic melanoma. Clin. Cancer Res., 2011, 17(24), 7732-7742.
[147]
Weide, B.; Eigentler, T.K.; Pflugfelder, A.; Zelba, H.; Martens, A.; Pawelec, G.; Giovannoni, L.; Ruffini, P.A.; Elia, G.; Neri, D.; Gutzmer, R.; Becker, J.C.; Garbe, C. Intralesional treatment of stage III metastatic melanoma patients with L19-IL2 results in sustained clinical and systemic immunologic responses. Cancer Immunol. Res., 2014, 2(7), 668-678.
[148]
Schliemann, C.; Palumbo, A.; Zuberbühler, K.; Villa, A.; Kaspar, M.; Trachsel, E.; Klapper, W.; Menssen, H.D.; Neri, D. Complete eradication of human B-cell lymphoma xenografts using rituximab in combination with the immunocytokine L19-IL2. Blood, 2009, 113(10), 2275-2283.
[149]
Danielli, R.; Patuzzo, R.; Di Giacomo, A.M.; Gallino, G.; Maurichi, A.; Di Florio, A.; Cutaia, O.; Lazzeri, A.; Fazio, C.; Miracco, C.; Giovannoni, L.; Elia, G.; Neri, D.; Maio, M.; Santinami, M. Intralesional administration of L19-IL2/L19-TNF in stage III or stage IVM1a melanoma patients: results of a phase II study. Cancer Immunol. Immunother., 2015, 64(8), 999-1009.
[150]
Larson, S.M.; Carrasquillo, J.A.; Cheung, N.K.; Press, O.W. Radioimmunotherapy of human tumours. Nat. Rev. Cancer, 2015, 15(6), 347-360.
[151]
Goldenberg, D.M.; Sharkey, R.M.; Paganelli, G.; Barbet, J.; Chatal, J.F. Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy. J. Clin. Oncol., 2006, 24(5), 823-834.
[152]
Orcutt, K.D.; Slusarczyk, A.L.; Cieslewicz, M.; Ruiz-Yi, B.; Bhushan, K.R.; Frangioni, J.V.; Wittrup, K.D. Engineering an antibody with picomolar affinity to DOTA chelates of multiple radionuclides for pretargeted radioimmunotherapy and imaging. Nucl. Med. Biol., 2011, 38(2), 223-233.
[153]
Sharkey, R.M.; McBride, W.J.; Karacay, H.; Chang, K.; Griffiths, G.L.; Hansen, H.J.; Goldenberg, D.M. A universal pretargeting system for cancer detection and therapy using bispecific antibody. Cancer Res., 2003, 63(2), 354-363.
[154]
Orcutt, K.D.; Ackerman, M.E.; Cieslewicz, M.; Quiroz, E.; Slusarczyk, A.L.; Frangioni, J.V.; Wittrup, K.D. A modular IgG-scFv bispecific antibody topology. Protein Eng. Des. Sel., 2010, 23(4), 221-228.
[155]
Cheal, S.M.; Xu, H.; Guo, H.F.; Zanzonico, P.B.; Larson, S.M.; Cheung, N.K. Preclinical evaluation of multistep targeting of diasialoganglioside GD2 using an IgG-scFv bispecific antibody with high affinity for GD2 and DOTA metal complex. Mol. Cancer Ther., 2014, 13(7), 1803-1812.
[156]
Allen, T.M. Ligand-targeted therapeutics in anticancer therapy. Nat. Rev. Cancer, 2002, 2(10), 750-763.
[157]
Schindler, J.; Sausville, E.; Messmann, R.; Uhr, J.W.; Vitetta, E.S. The toxicity of deglycosylated ricin A chain-containing immunotoxins in patients with non-Hodgkin’s lymphoma is exacerbated by prior radiotherapy: A retrospective analysis of patients in five clinical trials. Clin. Cancer Res., 2001, 7(2), 255-258.
[158]
Kowalski, M.; Guindon, J.; Brazas, L.; Moore, C.; Entwistle, J.; Cizeau, J.; Jewett, M.A.; MacDonald, G.C. A phase II study of oportuzumab monatox: an immunotoxin therapy for patients with noninvasive urothelial carcinoma in situ previously treated with bacillus Calmette-Guérin. J. Urol., 2012, 188(5), 1712-1718.
[159]
Borghaei, H.; Alpaugh, K.; Hedlund, G.; Forsberg, G.; Langer, C.; Rogatko, A.; Hawkins, R.; Dueland, S.; Lassen, U.; Cohen, R.B. Phase I dose escalation, pharmacokinetic and pharmacodynamic study of naptumomab estafenatox alone in patients with advanced cancer and with docetaxel in patients with advanced non-small-cell lung cancer. J. Clin. Oncol., 2009, 27(25), 4116-4123.
[160]
Eisen, T.; Hedlund, G.; Forsberg, G.; Hawkins, R. Naptumomab estafenatox: Targeted immunotherapy with a novel immunotoxin. Curr. Oncol. Rep., 2014, 16(2), 370.
[161]
Chandramohan, V.; Bigner, D.D. A novel recombinant immunotoxin-based therapy targeting wild-type and mutant EGFR improves survival in murine models of glioblastoma. OncoImmunology, 2013, 2(12), e26852.
[162]
Garnett, M.C. Targeted drug conjugates: principles and progress. Adv. Drug Deliv. Rev., 2001, 53(2), 171-216.
[163]
Kim, E.G.; Kim, K.M. Strategies and advancement in anti-body-drug conjugate optimization for targeted cancer thera-peutics. Biomol. Ther. (Seoul), 2015, 23(6), 493-509.
[164]
Kim, K.M.; McDonagh, C.F.; Westendorf, L.; Brown, L.L.; Sussman, D.; Feist, T.; Lyon, R.; Alley, S.C.; Okeley, N.M.; Zhang, X.; Thompson, M.C.; Stone, I.; Gerber, H.P.; Carter, P.J. Anti-CD30 diabody-drug conjugates with potent antitumor activity. Mol. Cancer Ther., 2008, 7(8), 2486-2497.
[165]
Richards, D.A.; Maruani, A.; Chudasama, V. Antibody fragments as nanoparticle targeting ligands: a step in the right direction. Chem. Sci. (Camb.), 2017, 8(1), 63-77.
[166]
Shargh, V.H.; Hondermarck, H.; Liang, M. Antibody-targeted biodegradable nanoparticles for cancer therapy. Nanomedicine (Lond.), 2016, 11(1), 63-79.
[167]
Wang, W.; Wang, E.Q.; Balthasar, J.P. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin. Pharmacol. Ther., 2008, 84(5), 548-558.
[168]
Peer, D.; Karp, J.M.; Hong, S.; Farokhzad, O.C.; Margalit, R.; Langer, R. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol., 2007, 2(12), 751-760.
[169]
Cheng, W.W.; Allen, T.M. Targeted delivery of anti-CD19 liposomal doxorubicin in B-cell lymphoma: A comparison of whole monoclonal antibody, Fab’ fragments and single chain Fv. J. Control. Release, 2008, 126(1), 50-58.
[170]
Sapra, P.; Moase, E.H.; Ma, J.; Allen, T.M. Improved therapeutic responses in a xenograft model of human B lymphoma (Namalwa) for liposomal vincristine versus liposomal doxorubicin targeted via anti-CD19 IgG2a or Fab’ fragments. Clin. Cancer Res., 2004, 10(3), 1100-1111.
[171]
Miller, K.; Cortes, J.; Hurvitz, S.A.; Krop, I.E.; Tripathy, D.; Verma, S.; Riahi, K.; Reynolds, J.G.; Wickham, T.J.; Molnar, I.; Yardley, D.A. HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician’s choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer. BMC Cancer, 2016, 16, 352.
[172]
Xiangbao, Y.; Linquan, W.; Mingwen, H.; Fan, Z.; Kai, W.; Xin, Y.; Kaiyang, W.; Huaqun, F. Humanized anti-VEGFR-2 ScFv-As2O3-stealth nanoparticles, an antibody conjugate with potent and selective anti-hepatocellular carcinoma activity. Biomed. Pharmacother., 2014, 68(5), 597-602.
[173]
Quarta, A.; Bernareggi, D.; Benigni, F.; Luison, E.; Nano, G.; Nitti, S.; Cesta, M.C.; Di Ciccio, L.; Canevari, S.; Pellegrino, T.; Figini, M. Targeting FR-expressing cells in ovarian cancer with Fab-functionalized nanoparticles: A full study to provide the proof of principle from in vitro to in vivo. Nanoscale, 2015, 7(6), 2336-2351.
[174]
Rabenhold, M.; Steiniger, F.; Fahr, A.; Kontermann, R.E.; Rüger, R. Bispecific single-chain diabody-immunoliposomes targeting endoglin (CD105) and fibroblast activation protein (FAP) simultaneously. J. Control. Release, 2015, 201, 56-67.
[175]
Iden, D.L.; Allen, T.M. In vitro and in vivo comparison of immunoliposomes made by conventional coupling techniques with those made by a new post-insertion approach. Biochim. Biophys. Acta, 2001, 1513(2), 207-216.
[176]
Li, W.M.; Mayer, L.D.; Bally, M.B. Prevention of antibody-mediated elimination of ligand-targeted liposomes by using poly(ethylene glycol)-modified lipids. J. Pharmacol. Exp. Ther., 2002, 300(3), 976-983.
[177]
Ludwig, D.L.; Pereira, D.S.; Zhu, Z.; Hicklin, D.J.; Bohlen, P. Monoclonal antibody therapeutics and apoptosis. Oncogene, 2003, 22(56), 9097-9106.
[178]
Reichert, J.M.; Rosensweig, C.J.; Faden, L.B.; Dewitz, M.C. Monoclonal antibody successes in the clinic. Nat. Biotechnol., 2005, 23(9), 1073-1078.
[179]
Adams, G.P.; Weiner, L.M. Monoclonal antibody therapy of cancer. Nat. Biotechnol., 2005, 23(9), 1147-1157.
[180]
Salomon, D.S.; Brandt, R.; Ciardiello, F.; Normanno, N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit. Rev. Oncol. Hematol., 1995, 19(3), 183-232.
[181]
Polanovski, O.L.; Lebedenko, E.N.; Deyev, S.M. ERBB oncogene proteins as targets for monoclonal antibodies. Biochemistry (Mosc.), 2012, 77(3), 227-245.
[182]
Rocha-Lima, C.M.; Soares, H.P.; Raez, L.E.; Singal, R. EGFR targeting of solid tumors. Cancer Contr., 2007, 14(3), 295-304.
[183]
Mendelsohn, J. Blockade of receptors for growth factors: an anticancer therapy--the fourth annual Joseph H Burchenal American Association of Cancer Research Clinical Research Award Lecture. Clin. Cancer Res., 2000, 6(3), 747-753.
[184]
Keating, G.M. Panitumumab: a review of its use in metastatic colorectal cancer. Drugs, 2010, 70(8), 1059-1078.
[185]
Mandal, M.; Adam, L.; Mendelsohn, J.; Kumar, R. Nuclear targeting of Bax during apoptosis in human colorectal cancer cells. Oncogene, 1998, 17(8), 999-1007.
[186]
Tortora, G.; Caputo, R.; Pomatico, G.; Pepe, S.; Bianco, A.R.; Agrawal, S.; Mendelsohn, J.; Ciardiello, F. Cooperative inhibitory effect of novel mixed backbone oligonucleotide targeting protein kinase A in combination with docetaxel and anti-epidermal growth factor-receptor antibody on human breast cancer cell growth. Clin. Cancer Res., 1999, 5(4), 875-881.
[187]
Reichert, J.M.; Dhimolea, E. The future of antibodies as cancer drugs. Drug Discov. Today, 2012, 17(17-18), 954-963.
[188]
Slamon, D.J.; Clark, G.M.; Wong, S.G.; Levin, W.J.; Ullrich, A.; McGuire, W.L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science, 1987, 235(4785), 177-182.
[189]
Hynes, N.E.; Lane, H.A. ERBB receptors and cancer: The complexity of targeted inhibitors. Nat. Rev. Cancer, 2005, 5(5), 341-354.
[190]
Cho, H.S.; Mason, K.; Ramyar, K.X.; Stanley, A.M.; Gabelli, S.B.; Denney, D.W., Jr; Leahy, D.J. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature, 2003, 421(6924), 756-760.
[191]
Agus, D.B.; Akita, R.W.; Fox, W.D.; Lewis, G.D.; Higgins, B.; Pisacane, P.I.; Lofgren, J.A.; Tindell, C.; Evans, D.P.; Maiese, K.; Scher, H.I.; Sliwkowski, M.X. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell, 2002, 2(2), 127-137.
[192]
Leung, K.M.; Batey, S.; Rowlands, R.; Isaac, S.J.; Jones, P.; Drewett, V.; Carvalho, J.; Gaspar, M.; Weller, S.; Medcalf, M.; Wydro, M.M.; Pegram, R.; Mudde, G.C.; Bauer, A.; Moulder, K.; Woisetschläger, M.; Tuna, M.; Haurum, J.S.; Sun, H. HER2-specific modified Fc fragment (Fcab) in-duces antitumor effects through degradation of HER2 and apoptosis. Mol. Ther., 2015, 23(11), 1722-1733.
[193]
Riedl, S.J.; Shi, Y. Molecular mechanisms of caspase regulation during apoptosis. Nat. Rev. Mol. Cell Biol., 2004, 5(11), 897-907.
[194]
de Miguel, D.; Lemke, J.; Anel, A.; Walczak, H.; Martinez-Lostao, L. Onto better TRAILs for cancer treatment. Cell Death Differ., 2016, 23(5), 733-747.
[195]
Liu, F.; Si, Y.; Liu, G.; Li, S.; Zhang, J.; Ma, Y. The tetravalent anti-DR5 antibody without cross-linking direct induces apoptosis of cancer cells. Biomed. Pharmacother., 2015, 70, 41-45.
[196]
Chuntharapai, A.; Dodge, K.; Grimmer, K.; Schroeder, K.; Marsters, S.A.; Koeppen, H.; Ashkenazi, A.; Kim, K.J. Isotype-dependent inhibition of tumor growth in vivo by monoclonal antibodies to death receptor 4. J. Immunol., 2001, 166(8), 4891-4898.
[197]
Dobson, C.L.; Main, S.; Newton, P.; Chodorge, M.; Cadwallader, K.; Humphreys, R.; Albert, V.; Vaughan, T.J.; Minter, R.R.; Edwards, B.M. Human monomeric antibody fragments to TRAIL-R1 and TRAIL-R2 that display potent in vitro agonism. MAbs, 2009, 1(6), 552-562.
[198]
Cheng, X.; Meng, Q.; Gao, C.; Zhuang, G.; Huang, X.; Zhang, J.; Liu, B.; Fan, X.; Zhang, M. Analysis of aDR5scFv with specific identification and function. Monoclon. Antib. Immunodiagn. Immunother., 2016, 35(1), 25-31.
[199]
Wang, W.; He, W.; Wang, L.; Zhang, G.; Gao, B. Pentamerisation of a scFv directed against TRAIL receptor 2 increases its antitumour efficacy. Immunol. Cell Biol., 2013, 91(5), 360-367.
[200]
Stieglmaier, J.; Bremer, E.; Kellner, C.; Liebig, T.M.; ten Cate, B.; Peipp, M.; Schulze-Koops, H.; Pfeiffer, M.; Bühring, H.J.; Greil, J.; Oduncu, F.; Emmerich, B.; Fey, G.H.; Helfrich, W. Selective induction of apoptosis in leukemic B-lymphoid cells by a CD19-specific TRAIL fusion protein. Cancer Immunol. Immunother., 2008, 57(2), 233-246.
[201]
Yan, C.; Li, S.; Li, Z.; Peng, H.; Yuan, X.; Jiang, L.; Zhang, Y.; Fan, D.; Hu, X.; Yang, M.; Xiong, D. Human umbilical cord mesenchymal stem cells as vehicles of CD20-specific TRAIL fusion protein delivery: A double-target therapy against non-Hodgkin’s lymphoma. Mol. Pharm., 2013, 10(1), 142-151.
[202]
ten Cate, B.; Bremer, E.; de Bruyn, M.; Bijma, T.; Samplonius, D.; Schwemmlein, M.; Huls, G.; Fey, G.; Helfrich, W. A novel AML-selective TRAIL fusion protein that is superior to Gemtuzumab Ozogamicin in terms of in vitro selectivity, activity and stability. Leukemia, 2009, 23(8), 1389-1397.
[203]
Schneider, B.; Münkel, S.; Krippner-Heidenreich, A.; Grunwald, I.; Wels, W.S.; Wajant, H.; Pfizenmaier, K.; Gerspach, J. Potent antitumoral activity of TRAIL through generation of tumor-targeted single-chain fusion proteins. Cell Death Dis., 2010, 1, e68.
[204]
Siegemund, M.; Pollak, N.; Seifert, O.; Wahl, K.; Hanak, K.; Vogel, A.; Nussler, A.K.; Göttsch, D.; Münkel, S.; Bantel, H.; Kontermann, R.E.; Pfizenmaier, K. Superior antitumoral activity of dimerized targeted single-chain TRAIL fusion proteins under retention of tumor selectivity. Cell Death Dis., 2012, 3, e295.
[205]
de Bruyn, M.; Wei, Y.; Wiersma, V.R.; Samplonius, D.F.; Klip, H.G.; van der Zee, A.G.; Yang, B.; Helfrich, W.; Bremer, E. Cell surface delivery of TRAIL strongly augments the tumoricidal activity of T cells. Clin. Cancer Res., 2011, 17(17), 5626-5637.
[206]
El-Mesery, M.; Trebing, J.; Schäfer, V.; Weisenberger, D.; Siegmund, D.; Wajant, H. CD40-directed scFv-TRAIL fusion proteins induce CD40-restricted tumor cell death and activate dendritic cells. Cell Death Dis., 2013, 4(11), e916.
[207]
Zhu, Y.; Choi, S.H.; Shah, K. Multifunctional receptor-targeting antibodies for cancer therapy. Lancet Oncol., 2015, 16(15), e543-e554.
[208]
Byrd, J.C.; Kitada, S.; Flinn, I.W.; Aron, J.L.; Pearson, M.; Lucas, D.; Reed, J.C. The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. Blood, 2002, 99(3), 1038-1043.
[209]
Alas, S.; Ng, C.P.; Bonavida, B. Rituximab modifies the cisplatin-mitochondrial signaling pathway, resulting in apoptosis in cisplatin-resistant non-Hodgkin’s lymphoma. Clin. Cancer Res., 2002, 8(3), 836-845.
[210]
Liu, Y.X.; Xiong, D.S.; Fan, D.M.; Xu, Y.F.; Yang, C.Z. Apoptosis of Raji cells by an anti-CD20 antibody HI47 and its fragments. Leuk. Res., 2004, 28(2), 209-211.
[211]
Cardarelli, P.M.; Quinn, M.; Buckman, D.; Fang, Y.; Colcher, D.; King, D.J.; Bebbington, C.; Yarranton, G. Binding to CD20 by anti-B1 antibody or F(ab’)(2) is sufficient for induction of apoptosis in B-cell lines. Cancer Immunol. Immunother., 2002, 51(1), 15-24.
[212]
Liu, Y.; Zheng, M.; Lai, Z.; Xiong, D.; Fan, D.; Xu, Y.; Peng, H.; Shao, X.; Xu, Y.; Yang, M.; Wang, J.; Liu, H.; Xie, Y.; Yang, C.; Zhu, Z. Inhibition of human B-cell lymphoma by an anti-CD20 antibody and its chimeric F(ab’)2 fragment via induction of apoptosis. Cancer Lett., 2004, 205(2), 143-153.
[213]
Bremer, E.; ten Cate, B.; Samplonius, D.F.; Mueller, N.; Wajant, H.; Stel, A.J.; Chamuleau, M.; van de Loosdrecht, A.A.; Stieglmaier, J.; Fey, G.H.; Helfrich, W. Superior activity of fusion protein scFvRit: sFasL over cotreatment with rituximab and Fas agonists. Cancer Res., 2008, 68(2), 597-604.
[214]
Mateo, V.; Lagneaux, L.; Bron, D.; Biron, G.; Armant, M.; Delespesse, G.; Sarfati, M. CD47 ligation induces caspase-independent cell death in chronic lymphocytic leukemia. Nat. Med., 1999, 5(11), 1277-1284.
[215]
Roué, G.; Bitton, N.; Yuste, V.J.; Montange, T.; Rubio, M.; Dessauge, F.; Delettre, C.; Merle-Béral, H.; Sarfati, M.; Susin, S.A. Mitochondrial dysfunction in CD47-mediated caspase-independent cell death: ROS production in the absence of cytochrome c and AIF release. Biochimie, 2003, 85(8), 741-746.
[216]
Kikuchi, Y.; Uno, S.; Kinoshita, Y.; Yoshimura, Y.; Iida, S.; Wakahara, Y.; Tsuchiya, M.; Yamada-Okabe, H.; Fukushima, N. Apoptosis inducing bivalent single-chain antibody fragments against CD47 showed antitumor potency for multiple myeloma. Leuk. Res., 2005, 29(4), 445-450.
[217]
Sagawa, M.; Shimizu, T.; Fukushima, N.; Kinoshita, Y.; Ohizumi, I.; Uno, S.; Kikuchi, Y.; Ikeda, Y.; Yamada-Okabe, H.; Kizaki, M. A new disulfide-linked dimer of a single-chain antibody fragment against human CD47 induces apoptosis in lymphoid malignant cells via the hypoxia inducible factor-1α pathway. Cancer Sci., 2011, 102(6), 1208-1215.
[218]
Ahmed, M.; Cheung, N.K. Engineering anti-GD2 monoclonal antibodies for cancer immunotherapy. FEBS Lett., 2014, 588(2), 288-297.
[219]
Cheever, M.A.; Allison, J.P.; Ferris, A.S.; Finn, O.J.; Hastings, B.M.; Hecht, T.T.; Mellman, I.; Prindiville, S.A.; Viner, J.L.; Weiner, L.M.; Matrisian, L.M. The prioritization of cancer antigens: A national cancer institute pilot project for the acceleration of translational research. Clin. Cancer Res., 2009, 15(17), 5323-5337.
[220]
Doronin, I.I.; Vishnyakova, P.A.; Kholodenko, I.V.; Ponomarev, E.D.; Ryazantsev, D.Y.; Molotkovskaya, I.M.; Kholodenko, R.V. Ganglioside GD2 in reception and transduction of cell death signal in tumor cells. BMC Cancer, 2014, 14, 295.
[221]
Mora, J. Dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma. Expert Rev. Clin. Pharmacol., 2016, 9(5), 647-653.
[222]
Brown, B.S.; Patanam, T.; Mobli, K.; Celia, C.; Zage, P.E.; Bean, A.J.; Tasciotti, E. Etoposide-loaded immunoliposomes as active targeting agents for GD2-positive malignancies. Cancer Biol. Ther., 2014, 15(7), 851-861.
[223]
Brignole, C.; Pastorino, F.; Marimpietri, D.; Pagnan, G.; Pistorio, A.; Allen, T.M.; Pistoia, V.; Ponzoni, M. Immune cell-mediated antitumor activities of GD2-targeted liposomal c-myb antisense oligonucleotides containing CpG motifs. J. Natl. Cancer Inst., 2004, 96(15), 1171-1180.
[224]
Di Paolo, D.; Ambrogio, C.; Pastorino, F.; Brignole, C.; Martinengo, C.; Carosio, R.; Loi, M.; Pagnan, G.; Emionite, L.; Cilli, M.; Ribatti, D.; Allen, T.M.; Chiarle, R.; Ponzoni, M.; Perri, P. Selective therapeutic targeting of the anaplastic lymphoma kinase with liposomal siRNA induces apoptosis and inhibits angiogenesis in neuroblastoma. Mol. Ther., 2011, 19(12), 2201-2212.
[225]
Baiu, D.C.; Artz, N.S.; McElreath, M.R.; Menapace, B.D.; Hernando, D.; Reeder, S.B.; Grüttner, C.; Otto, M. High specificity targeting and detection of human neuroblastoma using multifunctional anti-GD2 iron-oxide nanoparticles. Nanomedicine (Lond.), 2015, 10(19), 2973-2988.
[226]
Tivnan, A.; Orr, W.S.; Gubala, V.; Nooney, R.; Williams, D.E.; McDonagh, C.; Prenter, S.; Harvey, H.; Domingo-Fernández, R.; Bray, I.M.; Piskareva, O.; Ng, C.Y.; Lode, H.N.; Davidoff, A.M.; Stallings, R.L. Inhibition of neuroblastoma tumor growth by targeted delivery of microRNA-34a using anti-disialoganglioside GD2 coated nanoparticles. PLoS One, 2012, 7(5), e38129.
[227]
Pastorino, F.; Brignole, C.; Loi, M.; Di Paolo, D.; Di Fiore, A.; Perri, P.; Pagnan, G.; Ponzoni, M. Nanocarrier-mediated targeting of tumor and tumor vascular cells improves uptake and penetration of drugs into neuroblastoma. Front. Oncol., 2013, 3, 190.
[228]
Zubareva, A.A.; Boyko, A.A.; Kholodenko, I.V.; Rozov, F.N.; Larina, M.V.; Aliev, T.K.; Doronin, I.I.; Vishnyakova, P.A.; Molotkovskaya, I.M.; Kholodenko, R.V. Chitosan na-noparticles targeted to the tumor-associated ganglioside GD2. Russ. J. Bioorganic Chem., 2016, 42, 532.
[229]
Zeng, Y.; Huebener, N.; Fest, S.; Weixler, S.; Schroeder, U.; Gaedicke, G.; Xiang, R.; Schramm, A.; Eggert, A.; Reisfeld, R.A.; Lode, H.N. Fractalkine (CX3CL1)- and interleukin-2-enriched neuroblastoma microenvironment induces eradication of metastases mediated by T cells and natural killer cells. Cancer Res., 2007, 67(5), 2331-2338.
[230]
Otto, M.; Barfield, R.C.; Martin, W.J.; Iyengar, R.; Leung, W.; Leimig, T.; Chaleff, S.; Gillies, S.D.; Handgretinger, R. Combination immunotherapy with clinical-scale enriched human gammadelta T cells, hu14.18 antibody, and the immunocytokine Fc-IL7 in disseminated neuroblastoma. Clin. Cancer Res., 2005, 11(23), 8486-8491.
[231]
Wargalla, U.C.; Reisfeld, R.A. Rate of internalization of an immunotoxin correlates with cytotoxic activity against human tumor cells. Proc. Natl. Acad. Sci. USA, 1989, 86(13), 5146-5150.
[232]
Mujoo, K.; Reisfeld, R.A.; Cheung, L.; Rosenblum, M.G. A potent and specific immunotoxin for tumor cells expressing disialoganglioside GD2. Cancer Immunol. Immunother., 1991, 34(3), 198-204.
[233]
Thomas, P.B.; Delatte, S.J.; Sutphin, A.; Frankel, A.E.; Tagge, E.P. Effective targeted cytotoxicity of neuroblastoma cells. J. Pediatr. Surg., 2002, 37(3), 539-544.
[234]
Tur, M.K.; Sasse, S.; Stöcker, M.; Djabelkhir, K.; Huhn, M.; Matthey, B.; Gottstein, C.; Pfitzner, T.; Engert, A.; Barth, S. An anti-GD2 single chain Fv selected by phage display and fused to Pseudomonas exotoxin A develops specific cytotoxic activity against neuroblastoma derived cell lines. Int. J. Mol. Med., 2001, 8(5), 579-584.
[235]
Modak, S.; Cheung, N.K. Antibody-based targeted radiation to pediatric tumors. J. Nucl. Med., 2005, 46(Suppl. 1), 157S-163S.
[236]
Perez Horta, Z.; Goldberg, J.L.; Sondel, P.M. Anti-GD2 mAbs and next-generation mAb-based agents for cancer therapy. Immunotherapy, 2016, 8(9), 1097-1117.
[237]
Louis, C.U.; Savoldo, B.; Dotti, G.; Pule, M.; Yvon, E.; Myers, G.D.; Rossig, C.; Russell, H.V.; Diouf, O.; Liu, E.; Liu, H.; Wu, M.F.; Gee, A.P.; Mei, Z.; Rooney, C.M.; Heslop, H.E.; Brenner, M.K. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood, 2011, 118(23), 6050-6056.
[238]
Yankelevich, M.; Kondadasula, S.V.; Thakur, A.; Buck, S.; Cheung, N.K.; Lum, L.G. Anti-CD3 × anti-GD2 bispecific antibody redirects T-cell cytolytic activity to neuroblastoma targets. Pediatr. Blood Cancer, 2012, 59(7), 1198-1205.
[239]
Cheng, M.; Santich, B.H.; Xu, H.; Ahmed, M.; Huse, M.; Cheung, N.K. Successful engineering of a highly potent single-chain variable-fragment (scFv) bispecific antibody to target disialoganglioside (GD2) positive tumors. OncoImmunology, 2016, 5(6), e1168557.
[240]
Yoshida, S.; Fukumoto, S.; Kawaguchi, H.; Sato, S.; Ueda, R.; Furukawa, K.; Ganglioside, G.; Ganglioside, G. D2) in small cell lung cancer cell lines: enhancement of cell proliferation and mediation of apoptosis. Cancer Res., 2001, 61(10), 4244-4252.
[241]
Kowalczyk, A.; Gil, M.; Horwacik, I.; Odrowaz, Z.; Kozbor, D.; Rokita, H. The GD2-specific 14G2a monoclonal antibody induces apoptosis and enhances cytotoxicity of chemotherapeutic drugs in IMR-32 human neuroblastoma cells. Cancer Lett., 2009, 281(2), 171-182.
[242]
Aixinjueluo, W.; Furukawa, K.; Zhang, Q.; Hamamura, K.; Tokuda, N.; Yoshida, S.; Ueda, R.; Furukawa, K. Mechanisms for the apoptosis of small cell lung cancer cells induced by anti-GD2 monoclonal antibodies: Roles of anoikis. J. Biol. Chem., 2005, 280(33), 29828-29836.
[243]
Vishnyakova, P.A.; Doronin, I.I.; Kholodenko, I.V.; Rya-zantsev, D.Y.; Molotkovskaya, I.M.; Kholodenko, R.V. Caspases participation in the cell death, induced by GD2-specific monoclonal antibody. Bioorg. Khim., 2014, 40, 1-10.
[244]
Horwacik, I.; Rokita, H. Targeting of tumor-associated gangliosides with antibodies affects signaling pathways and leads to cell death including apoptosis. Apoptosis, 2015, 20(5), 679-688.
[245]
Tsao, C.Y.; Sabbatino, F.; Cheung, N.K.; Hsu, J.C.; Villani, V.; Wang, X.; Ferrone, S. Anti-proliferative and pro-apoptotic activity of GD2 ganglioside-specific monoclonal antibody 3F8 in human melanoma cells. OncoImmunology, 2015, 4(8), e1023975.
[246]
Sorkin, L.S.; Otto, M.; Baldwin, W.M., III; Vail, E.; Gillies, S.D.; Handgretinger, R.; Barfield, R.C.; Ming , Yu. H.; Yu, A.L. Anti-GD(2) with an FC point mutation reduces complement fixation and decreases antibody-induced allodynia. Pain, 2010, 149(1), 135-142.
[247]
Cochonneau, D.; Terme, M.; Michaud, A.; Dorvillius, M.; Gautier, N.; Frikeche, J.; Alvarez-Rueda, N.; Bougras, G.; Aubry, J.; Paris, F.; Birklé, S. Cell cycle arrest and apoptosis induced by O-acetyl-GD2-specific monoclonal antibody 8B6 inhibits tumor growth in vitro and in vivo. Cancer Lett., 2013, 333(2), 194-204.
[248]
Doronin, I.I.; Kholodenko, I.V.; Molotkovskaya, I.M.; Kholodenko, R.V. Preparation of Fab-fragments of GD2-specific antibodies and analysis of their antitumor activity in vitro. Bull. Exp. Biol. Med., 2013, 154(5), 658-663.
[249]
Kholodenko, I.V.; Doronin, I.I.; Vishnyakova, P.A.; Bolkhovitina, E.L.; Molotkovskaya, I.M.; Kholodenko, R.V. Antitumor activity of GD2-specific antibodies and their Fab-fragments in the mouse tumor model. Immunologiya (Russia), 2013, 34, 199-203.
[250]
Strohl, W.R.; Strohl, L.M. Therapeutic antibody engineering: Current and future advances driving the strongest growth area in the pharmaceutical industry 2012. 11
[251]
Jawa, V.; Cousens, L.; De Groote, A.S. Immunogenicity of
therapeutic fusion proteins: Contributory factors and clinical
experience Fusion protein technolo-gies for biopharmaceuticals:
applications and challenges, 2013. 150-175
[252]
Boder, E.T.; Midelfort, K.S.; Wittrup, K.D. Directed evolution of antibody fragments with monovalent femtomolar antigen-binding affinity. Proc. Natl. Acad. Sci. USA, 2000, 97(20), 10701-10705.
[253]
Rader, C. Overview on concepts and applications of Fab antibody fragments.. Curr. Protoc. Protein Sci; , 2009. Chapter 6, Unit 6.9
[254]
Strohl, W.R. Fusion proteins for half-life extension of bio-logics as a strategy to make biobetters. BioDrugs, 2015, 29(4), 215-239.
[255]
Chapman, A.P.; Antoniw, P.; Spitali, M.; West, S.; Stephens, S.; King, D.J. Therapeutic antibody fragments with prolonged in vivo half-lives. Nat. Biotechnol., 1999, 17(8), 780-783.
[256]
Kontermann, R.E. Strategies to extend plasma half-lives of recombinant antibodies. BioDrugs, 2009, 23(2), 93-109.
[257]
Werle, M.; Bernkop-Schnürch, A. Strategies to improve plasma half life time of peptide and protein drugs. Amino Acids, 2006, 30(4), 351-367.
[258]
Chapman, A.P. PEGylated antibodies and antibody fragments for improved therapy: A review. Adv. Drug Deliv. Rev., 2002, 54(4), 531-545.
[259]
Jevsevar, S.; Kunstelj, M.; Porekar, V.G. PEGylation of therapeutic proteins. Biotechnol. J., 2010, 5(1), 113-128.
[260]
Schlapschy, M.; Binder, U.; Börger, C.; Theobald, I.; Wachinger, K.; Kisling, S.; Haller, D.; Skerra, A. PASylation: a biological alternative to PEGylation for extending the plasma half-life of pharmaceutically active proteins. Protein Eng. Des. Sel., 2013, 26(8), 489-501.
[261]
Schellenberger, V.; Wang, C.W.; Geething, N.C.; Spink, B.J.; Campbell, A.; To, W.; Scholle, M.D.; Yin, Y.; Yao, Y.; Bogin, O.; Cleland, J.L.; Silverman, J.; Stemmer, W.P. A recombinant polypeptide extends the in vivo half-life of peptides and proteins in a tunable manner. Nat. Biotechnol., 2009, 27(12), 1186-1190.
[262]
Mishraa, P.; Nayakb, B.; Deya, R.K. PEGylation in anti-cancer therapy: An overview. Asian. J. Pharm. Sci., 2016, 11(3), 337-348.
[263]
Rudmann, D.G.; Alston, J.T.; Hanson, J.C.; Heidel, S. High molecular weight polyethylene glycol cellular distribution and PEG-associated cytoplasmic vacuolation is molecular weight dependent and does not require conjugation to proteins. Toxicol. Pathol., 2013, 41(7), 970-983.
[264]
Davé, E.; Adams, R.; Zaccheo, O.; Carrington, B.; Compson, J.E.; Dugdale, S.; Airey, M.; Malcolm, S.; Hailu, H.; Wild, G.; Turner, A.; Heads, J.; Sarkar, K.; Ventom, A.; Marshall, D.; Jairaj, M.; Kopotsha, T.; Christodoulou, L.; Zamacona, M.; Lawson, A.D.; Heywood, S.; Humphreys, D.P. Fab-dsFv: A bispecific antibody format with extended serum half-life through albumin binding. MAbs, 2016, 8(7), 1319-1335.
[265]
Adams, R.; Griffin, L.; Compson, J.E.; Jairaj, M.; Baker, T.; Ceska, T.; West, S.; Zaccheo, O.; Davé, E.; Lawson, A.D.; Humphreys, D.P.; Heywood, S. Extending the half-life of a fab fragment through generation of a humanized anti-human serum albumin Fv domain: An investigation into the correlation between affinity and serum half-life. MAbs, 2016, 8(7), 1336-1346.
[266]
Czajkowsky, D.M.; Hu, J.; Shao, Z.; Pleass, R.J. Fc-fusion proteins: New developments and future perspectives. EMBO Mol. Med., 2012, 4(10), 1015-1028.
[267]
Hutt, M.; Färber-Schwarz, A.; Unverdorben, F.; Richter, F.; Kontermann, R.E. Plasma half-life extension of small recombinant antibodies by fusion to immunoglobulin-binding domains. J. Biol. Chem., 2012, 287(7), 4462-4469.
[268]
Nguyen, A.; Reyes, A.E., II; Zhang, M.; McDonald, P.; Wong, W.L.; Damico, L.A.; Dennis, M.S. The pharmacokinetics of an albumin-binding Fab (AB.Fab) can be modulated as a function of affinity for albumin. Protein Eng. Des. Sel., 2006, 19(7), 291-297.
[269]
Andersen, J.T.; Cameron, J.; Plumridge, A.; Evans, L.; Sleep, D.; Sandlie, I. Single-chain variable fragment albumin fusions bind the neonatal Fc receptor (FcRn) in a species-dependent manner: implications for in vivo half-life evaluation of albumin fusion therapeutics. J. Biol. Chem., 2013, 288(33), 24277-24285.
[270]
Tijink, B.M.; Laeremans, T.; Budde, M.; Stigter-van Walsum, M.; Dreier, T.; de Haard, H.J.; Leemans, C.R.; van Dongen, G.A. Improved tumor targeting of anti-epidermal growth factor receptor nanobodies through albumin binding: Taking advantage of modular nanobody technology. Mol. Cancer Ther., 2008, 7(8), 2288-2297.
[271]
Müller, D.; Karle, A.; Meissburger, B.; Höfig, I.; Stork, R.; Kontermann, R.E. Improved pharmacokinetics of recombinant bispecific antibody molecules by fusion to human serum albumin. J. Biol. Chem., 2007, 282(17), 12650-12660.
[272]
Kenanova, V.E.; Olafsen, T.; Salazar, F.B.; Williams, L.E.; Knowles, S.; Wu, A.M. Tuning the serum persistence of human serum albumin domain III: Diabody fusion proteins. Protein Eng. Des. Sel., 2010, 23(10), 789-798.
[273]
Sleep, D.; Cameron, J.; Evans, L.R. Albumin as a versatile platform for drug half-life extension. Biochim. Biophys. Acta, 2013, 1830(12), 5526-5534.
[274]
Zhao, S.; Zhang, Y.; Tian, H.; Chen, X.; Cai, D.; Yao, W.; Gao, X. Extending the serum half-life of G-CSF via fusion with the domain III of human serum albumin. BioMed Res. Int., 2013, 2013, 107238.
[275]
Podust, V.N.; Balan, S.; Sim, B.C.; Coyle, M.P.; Ernst, U.; Peters, R.T.; Schellenberger, V. Extension of in vivo half-life of biologically active molecules by XTEN protein polymers. J. Control. Release, 2016, 240, 52-66.
[276]
Floss, D.M.; Schallau, K.; Rose-John, S.; Conrad, U.; Scheller, J. Elastin-like polypeptides revolutionize recombinant protein expression and their biomedical application. Trends Biotechnol., 2010, 28(1), 37-45.
[277]
Yuen, K.C.; Conway, G.S.; Popovic, V.; Merriam, G.R.; Bailey, T.; Hamrahian, A.H.; Biller, B.M.; Kipnes, M.; Moore, J.A.; Humphriss, E.; Bright, G.M.; Cleland, J.L. A long-acting human growth hormone with delayed clearance (VRS-317): Results of a double-blind, placebo-controlled, single ascending dose study in growth hormone-deficient adults. J. Clin. Endocrinol. Metab., 2013, 98(6), 2595-2603.
[278]
Cleland, J.L.; Silverman, J.; Wang, C-W.; Geething, N.; Spink, B.; Campbell, A.; To, W.; Scholle, M.D.; Yin, Y.; Yao, Y.; Stemmer, W.P.C.; Schellenberger, V. An extended halflife exenatide construct for weekly administration in the treatment of diabetes mellitus. 2009. American Diabetes Association 69th Scientific Sessions New Orleans, LA.
